Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 May;25(5):1199-207.
doi: 10.1007/s11136-015-1140-2. Epub 2015 Sep 30.

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

Costel Chirila  1 , Qingyao Zheng  2 , Eric Davenport  2 , Dagmar Kaschinski  3 , Egon Pfarr  4 , Thomas Hach  4 , Roberto Palencia  3
Affiliations
Comparative Study

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

Costel Chirila et al. Qual Life Res. 2016 May.

Abstract

Purpose: This exploratory analysis assessed and compared patients' treatment satisfaction with empagliflozin plus metformin versus glimepiride plus metformin, using data obtained from the Diabetes Treatment Satisfaction Questionnaire, status version (DTSQs) collected in a randomized, double-blind, double-dummy clinical trial.

Methods: Observed values for DTSQs scale score and each of its eight items were summarized by visit and treatment arm. Changes from baseline in these scores were analyzed using linear mixed models for repeated measures.

Results: The baseline scale score and item scores were comparable between empagliflozin plus metformin (n = 765) and glimepiride plus metformin (n = 780). Compared with baseline, patients reported significant treatment satisfaction increases and significant decreases in perceived hyperglycemia with both treatments at all visits. Also, compared with baseline, a significant increase in perceived frequency of hypoglycemia was observed in the glimepiride treatment group at all visits. No statistically significant treatment difference was observed in DTSQs scale score and its items at week 104. The difference between the treatment groups was significant and in favor of empagliflozin from week 28 onward for perceived frequency of hyperglycemia (P ≤ 0.006) and perceived frequency of hypoglycemia (P ≤ 0.011).

Conclusions: Despite positive trends in favor of empagliflozin, there was no significant difference in DTSQs scale score between empagliflozin and glimepiride at 104 weeks. However, when compared with glimepiride, empagliflozin demonstrated significantly lower perceived frequency of hyperglycemia and hypoglycemia at all visits from week 28 onward. This finding is consistent with the clinical results reported for the EMPA-REG H2H-SU trial.

Keywords: Diabetes Treatment Satisfaction Questionnaire; Empagliflozin; Glimepiride; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Unadjusted mean scores by time: empagliflozin 25 mg versus glimepiride 1–4 mg. DTSQs diabetes treatment satisfaction questionnaire, status version
See this image and copyright information in PMC

References

    1. International Diabetes Federation. (2013). IDF diabetes atlas (6th ed.). http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 26 Nov 2014.
    1. Pyerot M, Rubin RR. How does treatment satisfaction work? Modeling determinants of treatment satisfaction and care. Diabetes Care. 2009;32:1411–1417. doi: 10.2337/dc08-2256. - DOI - PMC - PubMed
    1. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: Report of a working group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabetic Medicine. 1994;11:510–516. doi: 10.1111/j.1464-5491.1994.tb00316.x. - DOI - PubMed
    1. Bradley C, Gilbride CJB. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: The role of once-daily insulin glargine. Diabetes, Obesity and Metabolism Journal. 2008;10(suppl 2):50–65. doi: 10.1111/j.1463-1326.2008.00871.x. - DOI - PubMed
    1. Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. The American Journal of Medicine. 2010;123:S12–S18. doi: 10.1016/j.amjmed.2009.12.005. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources